Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs

References

• Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. doi:10.1056/NEJMoa2002032.
   PubMed Web of Science ®Google Scholar
• Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038–44. doi:10.1093/eurheartj/ehaa623.
   PubMed Web of Science ®Google Scholar
• Fosse JH, Haraldsen G, Falk K, Edelmann R. Endothelial cells in emerging viral infections. Front Cardiovasc Med. 2021 Feb 24. doi:10.3389/fcvm.2021.619690.
   PubMed Web of Science ®Google Scholar
• Fedson DS. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med. 2016;4:421. doi:10.21037/atm.2016.11.03.
   PubMed Web of Science ®Google Scholar
• Zhou T, Su TT, Mudianto T, Wang J. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. J Exp Med. 2020 Oct 5;217:e20200674. doi:10.1084/jem.20200674.
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–74. doi:10.1038/s41577-020-0311-8.
   PubMed Web of Science ®Google Scholar
• Grasselli G, Tonetti T, Protti A, Langer T, Girardis M, Bellani G, Laffey J, Carrafiello G, Carsana L, Rizzuto C, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med. 2020;8:1201–08. doi:10.1016/S2213-2600(20)30370-2.
   PubMed Web of Science ®Google Scholar
• Lee S, Channappanavar R, Kanneganti T-D. Coronaviruses: innate immunity, inflammasome activation, inflammatory cell death, and cytokines. Trends Immunol. 2020;41:1083–99. doi:10.1016/j.it.2020.10.005.
   PubMed Web of Science ®Google Scholar
• El Baba R, Herbein G. Management of epigenomic networks entailed in coronavirus infections and COVID-19. Clin Epigenetics. 2020;12:118. doi:10.1186/s13148-020-00912-7.
   PubMed Web of Science ®Google Scholar
• Sparks MA, South AM, Badley AD, Baker-Smith CM, Batlle D, Bozkurt B, Cattaneo R, Crowley SD, Dell’Italia LJ, Ford AL, et al. Severe acute respiratory syndrome coronavirus 2, COVID-19, and the renin-angiotensin system: pressing needs and best research practices. Hypertension. 2020;76(5):1350–67. doi:10.1161/HYPERTENSIONAHA.120.15948.
   PubMed Web of Science ®Google Scholar
• Stein RA, Young LM. From ACE2 to COVID-19: a multiorgan endothelial disease. Int J Infect Dis. 2020;100:425–30. doi:10.1016/j.ijid.2020.08.083.
   PubMed Web of Science ®Google Scholar
• Teuwen L-A, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20(7):389–91. doi:10.1038/s41577-020-0343-0.
   PubMed Web of Science ®Google Scholar
• Rovas A, Osiaevi I, Buscher K, Sackarnd J, Tepasse P-R, Fobker M, Kuhn J, Braune S, Gobel U, Tholking G, et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis. 2021;24(1):135–47. doi:10.1007/s10456-020-09753-7.
   Web of Science ®Google Scholar
• Smadja DM, Guerin CL, Chocron R, Yatim N, Boussier J, Gendron N, Khider L, Hadjadj J, Goudot G, Debuc B, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis. 2020;23(4):611–20. doi:10.1007/s10456-020-09730-0.
   PubMed Web of Science ®Google Scholar
• Yamaoka-Tojo M. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19. Biomed J. 2020;43(5):399–413. doi:10.1016/j.bj.2020.08.007.
   PubMed Web of Science ®Google Scholar
• Evans PC, Rainger GE, Mason JC, Guzik TJ, Osto E, Stamataki Z. Endothelial dysfunction in COVID-19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC council of basic cardiovascular science. Cardiovasc Res. 2020;116(14):2177–84. doi:10.1093/cvr/cvaa230.
   Web of Science ®Google Scholar
• Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16(10):581–89. doi:10.1038/s41584-020-0474-5.
   Web of Science ®Google Scholar
• Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020;48(9):1358–64. doi:10.1097/CCM.0000000000004458.
   PubMed Web of Science ®Google Scholar
• Lu Y-F, Pan L-Y, Zhang -W-W, Cheng F, Hu S-S -S-S, Zhang X, Jiang H-Y. A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int J Infect Dis. 2020;100:34–41. doi:10.1016/j.ijid.2020.08.023.
   PubMed Web of Science ®Google Scholar
• Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020;130(11):6151–57. doi:10.1172/JCI141374.
   PubMed Web of Science ®Google Scholar
• Godoy LC, Goligher EC, Lawler PR, Slutsky AS, Zarychanski R. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. CMAJ. 2020;192(40):E1156–E1161. doi:10.1503/cmaj.201240.
   PubMed Web of Science ®Google Scholar
• Kvernland A, Kumar A, Yaghi S, Raz E, Frontera J, Lewis A, Czeisler B, Kahn DE, Zhou T, Ishida K et al. Anticoagulation use and hemorrhagic stroke in SARS-CoV-2 patients treated at a New York healthcare system. Neurocrit Care. 2020 Aug 24;(9):1–12. doi:10.1007/s12028-020-01077-0.
   Google Scholar
• Horie S, McNicholas B, Rezoagli E, Pham T, Curley G, McAuley D, O’Kane C, Nichol A, Dos Santos C, Rocco PRM, et al. Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive Care Medicine. 2020;46(12):2265–83. doi:10.1007/s00134-020-06141-z.
   PubMed Web of Science ®Google Scholar
• Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020;72:1479–508. doi:10.1007/s43440-020-00155-6.
   PubMed Web of Science ®Google Scholar
• Riva L, Yuan S, Yin X, Martin-Sancho LM, Matsunaga N, Pache L, Burgstaller-Muehlbacher S, De Jesus PD, Teriete P, Hull MV, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113–19. doi:10.1038/s41586-020-2577-1.
   PubMed Web of Science ®Google Scholar
• Farne H, Kumar K, Ricthie A, Finney LJ, Johnston SL, Singanayagam A. Repurposing existing drugs for the treatment of COVID-19. Ann Am Thorac Soc. 2020;17:1186–94. doi:10.1513/AnnalsATS.202005-566FR.
   PubMed Web of Science ®Google Scholar
• Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Jureka AS, Obernier K, Guo JZ, Batra J, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020 Dec 4;370:eabe9403. doi:10.1126/science.abe9403.
   PubMed Web of Science ®Google Scholar
• Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, Worrall D, Giguel F, Piechocka-Trocha A, Atyeo C, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11:5493. doi:10.1038/s41467-020-19057-5.
   PubMed Web of Science ®Google Scholar
• Bermejo-Martin JF, Gonzales-Rivera M, Almansa R, Micheloud D, Tedim AP, Dominguez-Gil M, Resino S, Martin-Fernandez M, Mura PR, Perez-Garcia F, et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit Care. 2020;24:691. doi:10.1186/s13054-020-03398-0.
   PubMed Web of Science ®Google Scholar
• Wofel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, et al. Virological assessment of hospitalized patients with COVID-19. Nature. 2020;581:465–69. doi:10.1038/s41586-020-2196-x.
   PubMed Web of Science ®Google Scholar
• Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, Ahern S, Carty PG, O’Brien KK, O’Murchu E, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020;81:357–71. doi:10.1016/j.jinf.2020.06.067.
   PubMed Web of Science ®Google Scholar
• WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo A-M, Preziosi M-P, Sathiyamoorthy V, Karim Q, Alejandra MM, Garcia C, Kieny M-P, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384:497–511. doi:10.1056/NEJMoa2023184.
   PubMed Web of Science ®Google Scholar
• Simonovich VA, Pratx LDB, Scibona P, Beruto MV, Vallone MG, Vazquez C, Savoy N, Giunta DH, Perez LG, Sanchez MDL, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619–29. doi:10.1056/NEJMoa2031304.
   PubMed Web of Science ®Google Scholar
• ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, Barkauskas C, Holland T, Gottlieb R, Sandkovsky U, Brown S, Knowlton K, Self W, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2021;384:905–14. doi:10.1056/NEJMoa2033130.
   PubMed Web of Science ®Google Scholar
• Thomson EC, Rosen LE, Shepherd JG, Spreafico R, Da Silva Filipe A, Wojcechowskyj JA, Davis C, Piccoli L, Pascall DJ, Dillen J, et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021;184:1171–87.e20. doi:10.1016/jcell.2021.01.037.
   PubMed Web of Science ®Google Scholar
• Cele S, Gazy I, Jackson L, Hwa S-H, Tegally H, Lustig G, Giandhari J, Pillay S, Wilkinson E, Naidoo Y, et al. Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. Nature. 2021;593:142–46. doi:10.1038/s41586-021-03471-w.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–35. doi:10.1038/s41586-021-03398-2.
   PubMed Web of Science ®Google Scholar
• Pirofski L-A, Casadevall A. Pathogenesis of COVID-19 from the perspective of the damage-response framework. mBio. 2020;11:e01175–20. doi:10.1128/mBio.01175-20.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group, Horby P, Lim W, Emberson JR, Mafham M, Bell J, Linsell L, Staplin N, Brightling C, Ustianowski A, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. doi:10.1056/NEJMoa2021436.
   PubMed Web of Science ®Google Scholar
• WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Jac S, Murthy S, Diaz J, Slutsky A, Villar J, Angus D, Annane D, Azvedo L, Berwanger O, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:330–41. doi:10.1001/jama.2020.17023.
   Web of Science ®Google Scholar
• Matthay MA, Thompson BT. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. Lancet Respir Med. 2020;8:1170–72. doi:10.1016/S2213-2600(20)30503-8.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–45. doi:10.1016/S0140-6736(21)00676-0.
   PubMed Web of Science ®Google Scholar
• REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-puijk W, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19.N Engl J Med. 2021;384:1491–1502. doi:10.1056/NEJMoa2100433.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turra C, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:24–31. doi:10.1001/jamainternmed.2020.6615.
   PubMed Web of Science ®Google Scholar
• Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;18:32–40. doi:10.1001/jamainternmed.2020.6820.
   Web of Science ®Google Scholar
• Rosas IO, Brau N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021 Feb 25. doi:10.1056/NEJMoa2028700.
   Web of Science ®Google Scholar
• Rubin EJ, Longo DL, Baden LR. Interleukin-6 receptor inhibition in Covid-19 - cooling the inflammatory soup. N Engl J Med. 2021;384:1564–65. doi:10.1056/NEJMe2103108.
   PubMed Web of Science ®Google Scholar
• Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013;99:417–35. doi:10.1016/j.antiviral.2013.06.018.
   PubMed Web of Science ®Google Scholar
• Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120:229–43. doi:10.1161/CIRCRESAHA.116.308537.
   PubMed Web of Science ®Google Scholar
• Parihar SP, Guler R, Brombacher F. Statins: a viable candidate for host-directed therapy against infectious diseases. Nat Rev Immunol. 2019;19:104–17. doi:10.1038/s41577-018-0094-3.
   PubMed Web of Science ®Google Scholar
• Gomes Silva IV, de Figueiredo RC, Alves Rios DR. Effect of different classes of antihypertensive drugs on endothelial function and inflammation. Int J Mol Sci. 2019;20:3458. doi:10.3390/ijms20143458.
   PubMed Web of Science ®Google Scholar
• Nagele MP, Haubner B, Tanner FC, Ruchitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis. 2020;314:58–62. doi:10.1016/j.atherosclerosis.2020.10.014.
   PubMed Web of Science ®Google Scholar
• Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, Howe B, Jones D, Joyce C, Kostner K, et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med. 2013;187:743–50. doi:10.1164/rccm.201209-1718OC.
   PubMed Web of Science ®Google Scholar
• De Roquetaillade C, Jamme M, Charpentier J, Chiche JD, Cariou A, Mira JP, Pene F, Litjos J-F. Hemodynamic impact of cardiovascular antihypertensive medications in patients with sepsis-related acute circulatory failure. Shock. 2020;54:315–20. doi:10.1097/SHK.0000000000001524.
   PubMed Web of Science ®Google Scholar
• Koh KK, Sakuma I, Shimada K, Hayashi T, Quon MJ. Combining potent statin therapy with other drugs to optimize simultaneous cardiovascular and metabolic benefits while minimizing adverse events. Korean Circ J. 2017;47:432–39. doi:10.4070/kcj.2016.0406.
   PubMed Web of Science ®Google Scholar
• Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis. 2006;43:199–205. doi:10.1086/505116.
   PubMed Web of Science ®Google Scholar
• Fedson DS, Rordam OM. Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers. Int J Infect Dis. 2015;36:80–84. doi:10.1016/j.ijid.2015.04.019.
   PubMed Web of Science ®Google Scholar
• Fedson DS, Opal SM, Rordam OM. Hiding in plain sight; an approach to treating patients with severe COVID-19 infection. mBio. 2020;11:e00398–20. doi:10.1128/mBio.00398-20.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. doi:10.1016/S0140-6736(20)30566-3.
   PubMed Web of Science ®Google Scholar
• Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170:244–56. doi:10.1093/aje/kwp107.
   PubMed Web of Science ®Google Scholar
• Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25:1–21. doi:10.1214/09-STS313.
   PubMed Web of Science ®Google Scholar
• Austin PC, Fine JP. Propensity-score matching with competing risks in survival analysis. Stat Med. 2019;38:751–77. doi:10.1002/sim.8008.
   PubMed Web of Science ®Google Scholar
• So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis. BMJ. 2020;371:m4750. doi:10.1136/bmj.m4750.
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, Lei F, Chen -M-M, Yang H, Bai L, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32:176–87. doi:10.1016/j.cmet.2020.06.015.
   PubMed Web of Science ®Google Scholar
• Mallow PJ, Belk KW, Topmiller M, Hooker EA. Outcomes of hospitalized COVID-19 patients by risk factors: results from a United States hospital claims database. J Health Econ Outcomes Res. 2020;7:165–74. doi:10.36469/jheor.2020.17331.
   PubMedGoogle Scholar
• Fan Y, Guo T, Yan F, Gong M, Zhang XA, Li C, He T, Luo H, Zhang L, Chen M, et al. Association of statin use with the in-hospital outcomes of 2019-coronavirus disease patients: a retrospective study. Front Med (Lausanne). 2020;7:584870. doi:10.3389/fmed.2020.584870.
   PubMed Web of Science ®Google Scholar
• Masana L, Correig E, Rodriguez-Borjabad C, Anoro E, Arroyo JA, Jerico C, Pedragosa A, la Miret M, Naf S, Pardo A, et al. Effect of statin therapy on SARS-CoV-2 -related mortality in hospitalized patients. Eur Heart J Cardiovasc Pharmacother. 2020 Nov 2; pvaa128. doi:10.1093/ehjcvp/pvaa128.
   Google Scholar
• Lam KW, Chow KW, Vo J, Hou W, Li H, Richman PS, Mallipattu S, Skopicki HA, Singer AJ, Duong TQ. Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcomes. J Infect Dis. 2020;222:1256–64. doi:10.1093/infdis/jiaa447.
   PubMed Web of Science ®Google Scholar
• Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, Rodriguez-Mori JE, Renna N, Chang TI, Corrales-Medina V, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9:275–84. doi:10.1016/S2213-2600(20)30558-0.
   PubMed Web of Science ®Google Scholar
• McCarthy CP, Murphy S, Jones-O’Connor M, Olshan DS, Khambhati JR, Rehman S, Cadigan JB, Cui J, Meyerowitz E, Phillippides G, et al. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. EClinicalMedicine. 2020;26:100504. doi:10.1016/j.eclinm.2020.100504.
   PubMedGoogle Scholar
• Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, Longhurst CA, Criqui MH, Messer K. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol. 2020;136:149–55. doi:10.1016/j.amjcard.2020.09.012.
   PubMed Web of Science ®Google Scholar
• Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open. 2020 Dec 1;3:e2029058. doi:10.1001/jamanetworkopen.2020.29058.
   PubMed Web of Science ®Google Scholar
• Kow CS, Hasan SS. Meta-analysis of effectiveness of statins in patients with severe COVID-19. Am J Cardiol. 2020;134:153–55. doi:10.1016/j.amjcard.2020.08.004.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Statins and clinical outcomes with COVID-19: meta-analyses of observational studies. Diabetes Metab. 2020 Dec 23;47(6):101220. doi:10.1016/j.diabet.2020.101220.
   Web of Science ®Google Scholar
• Nicholson CJ, Wooster L, Sigurslid HH, Li RF, Jiang W, Tian W, Cardenas CL, Malhotra R. Estimating risk of mechanical ventilation and mortality among adult COVID-19 patients admitted to mass general brigham: the VICE and DICE scores. EClinicalMedicine. 2021 Mar;33:100765. doi:10.1016/j.eclinm.2021.100765.
   Google Scholar
• Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA, Redfors B, Eckhardt C, Bikdeli B, Platt J, Nalbandian A, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun. 2021;12:1325. doi:10.1038/s41467-021-21553-1.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ; National Registry of Myocardial infarction 4 Investigators. Effect of statins use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96:611–16. doi:10.1016/j.amjcard.2005.04.029.
   PubMed Web of Science ®Google Scholar
• Cubeddu LX, Seamon MJ. Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy. 2006;26:1288–96. doi:10.1592/phco.26.9.1288.
   PubMed Web of Science ®Google Scholar
• Fedson DS. Statin treatment of COVID-19. Am J Cardiol. 2020;136:171–73. doi:10.1016/j.amjcard.2020.09.050.
   PubMed Web of Science ®Google Scholar
• Iqbal Z, Ho JH, Adam S, France M, Syed A, Neely D, Rees A, Khatib R, Cegla J, Byrne C, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: an expert panel position statement from HEART UK. Atherosclerosis. 2020;313:126–36. doi:10.1016/j.atherosclerosis.2020.09.008.
   PubMed Web of Science ®Google Scholar
• ESC Council on Hypertension. Position statement of the ESC Council on hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020 [accessed 29 Dec 2020]. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the- esc-council-on-hypertension-on-ace-inhibitors-and-ang .
   Google Scholar
• Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, Sule G, Gockman K, Madison JA, Zuo M, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12:eabd3876. doi:10.1126/scitranslmed.abd3876.
   PubMed Web of Science ®Google Scholar
• Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021 May 19. doi:10.1038/s41586-021-03631-y.
   Web of Science ®Google Scholar
• Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Phillippot Q, Rosain J, Beziat V, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23;370(6515):eabd4585. doi:10.1126/science.abd4585.
   Web of Science ®Google Scholar
• Hughes S. COVID-19 anticoagulation trials ‘paused’ for futility, safety. Medscape Internal Med. 2020 Dec 22 [accessed 15 Jan 2021]. medscape.com .
   Google Scholar
• Bianconi V, Sahebkar A, Banach M, Pirro M. Statins, hemostatic factors and thrombotic risk. Curr Opin Cardiol. 2017;32:460–66. doi:10.1097/HCO.0000000000000397.
   PubMed Web of Science ®Google Scholar
• Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol. 2017;4:e83–e93. doi:10.1016/S2352-3026(16)30184-3.
   PubMed Web of Science ®Google Scholar
• Meroni PL, Raschi E, Testoni C. Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention. Autoimmun Rev. 2002;1:55–60. doi:10.1016/s1568-9972(01)00014-3.
   PubMedGoogle Scholar
• Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–32. doi:10.1016/S0140-6736(20)32656-8.
   PubMed Web of Science ®Google Scholar
• De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tre G, Belmans L, Dobson R, Wynendaele E, Van De Wiele C, Vandaele F, et al. The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents. J Am Med Dir Assoc. 2020;21:909–14.e2. doi:10.1016/j.jamda.2020.06.018.
   PubMed Web of Science ®Google Scholar
• Kalil AC. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020;323:1897–98. doi:10.1001/jama.2020.4742.
   PubMed Web of Science ®Google Scholar
• Fanaroff AC, Califf RM, Harrington RA, Granger CB, McMurray JJV, Patel MR, Bhatt DL, Windecker S, Hernandez AF, Gibson SM, et al. Randomized trials versus common sense and clinical observation: JACC review topic of the week. J Am Coll Cardiol. 2020;76:580–89. doi:10.1016/j.jacc.2020.05.069.
   PubMed Web of Science ®Google Scholar
• Trump S, Lukassen S, Anker MS, Chua RL, Liebig J, Thurmann L, Corman VM, Binder M, Loske J, Klasa C, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat Biotechnol. 2020 Dec 24. doi:10.1038/s41587-020-00796-1.
   Web of Science ®Google Scholar
• Varshney AS, Wang DE, Bhatt AS, Blood A, Sharkawi MA, Siddiqi HK, Vaduganathan M, Monteleone PP, Patel MR, Jones WS, et al. Characteristics of clinical trials evaluating cardiovascular therapies for coronavirus disease 2019 registered on ClinicalTrials.gov: a cross-sectional analysis. Am Heart J. 2021;232:105–15. doi:10.1016/j.ahj.2020.10.065.
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz R. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–92. doi:10.1056/NEJM200006223422507.
   PubMed Web of Science ®Google Scholar
• Fedson DS. COVID-19, host response treatment, and the need for political leadership. J Public Health Policy. 2021;42:6–14. doi:10.1057/s41271-020-00266-7.
   PubMed Web of Science ®Google Scholar
• Angus DC. Optimizing the trade-off between learning and doing in a pandemic. JAMA. 2020;323:1895–96. doi:10.1001/jama.2020.4984.
   PubMed Web of Science ®Google Scholar
• Fedson DS. Clinician-initiated research on treating the host response to pandemic influenza. Hum Vaccin Immunother. 2018;14:790–95. doi:10.1080/21645515.2017.1378292.
   PubMed Web of Science ®Google Scholar